On November 9, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, reported that it has completed a pre-clinical study using its proprietary and novel RCC-33 formulation on human biopsies, obtained under a Helsinki Committee approved protocol (Press release, Cannabics Pharmaceuticals, NOV 9, 2020, View Source [SID1234570658]). The results show an antitumor synergistic effect of the active compounds, thus confirming the company’ previously obtained data on the antitumor properties of the drug candidate when screened on colorectal cell lines.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Eyal Ballan, Cannabics Pharmaceuticals’ CTO said: "the study results brings us one step closer in preparing our submission to the U.S. Food and Drug Administration for a pre-IND meeting. Our next step will be launching a study on mice to try and demonstrate the same synergistic effect and see tumor growth attenuation in-vivo."